Obsidian Therapeutics to Present Preclinical Data from cytoDRiVE® Platform and Pipeline at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022
|
Preclinical data highlight numerous pipeline advancements: cytoTIL15™ cells armed with combination-cytokines modulate the tumor microenvironment (TME); spatial profiling of cytoTIL15 cells in PDX models provides greater mechanistic understanding of cell-killing function; and IL12 armored T-cells with precise regulation show anti-tumor activity in solid tumor models. CAMBRIDGE, Mass., Nov. 7, 2022 /PRNewswire/ -- Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it will present preclinical data highlighting its recent cytoDRiVE® platform and pipeline advances during the poster sessions at the upcoming SITC Annual Meeting 2022. The abstracts have been posted to the SITC Online Itinerary Planner, will be published in the Journal for ImmunoTherapy of Cancer (JITC) supplement, and are detailed below.
Obsidian will present data from their cytoDRiVE platform for multiple applications, including novel advancements in cytoTIL engineering. New data to be presented highlight developments in cytoTIL15 therapies, in which engineered TIL expressing both membrane-bound IL15 and a combination-cytokine (either IFN-alpha, IL18 or an undisclosed member of the TNF superfamily) demonstrate in vivo persistence, modulation of the TME and anti-tumor activity. Armoring cytoTIL15 therapies with these potent immune mediators may expand the potential reach of cytoTIL therapies to solid tumors marked by an immunosuppressive TME. Additionally, Obsidian will share digital spatial profiling data showing that in an allogeneic melanoma PDX model, cytoTIL15 cells upregulate cell-killing functions while downregulating exhaustion markers. Obsidian will also present advancements to their cytoDRiVE platform to enable enhanced regulation of IL-12 armored T-cells in preclinical solid tumor models. "Obsidian's research advances highlight the versatility of our cytoDRiVE platform to engineer orthogonal features into cytoTIL15 therapies that will remodel the TME and may expand the potential reach of our IL2-free cytoTIL therapies to solid tumors with immunosuppressive microenvironments where clinical development of TIL therapies has been limited," said Jan ter Meulen, M.D. Ph.D., Chief Scientific Officer of Obsidian Therapeutics. "We are pleased with this rapid progress of our pipeline, further building on our lead cytoTIL15 therapy, OBX-115, which is currently enrolling a Phase I clinical trial." Details of the presentations are as follows: Title: Enhancers of innate and adaptive immunity combine with membrane bound IL15 to increase the efficacy of tumor infiltrating lymphocyte (TIL) therapy for tumors with immunosuppressive microenvironments Title: Digital spatial profiling and antigen-dependent phenotypic analysis of IL15-engineered tumor-infiltrating lymphocytes (cytoTIL15™ therapy) in an allogeneic melanoma PDX model Title: Pharmacologically-controlled expression of membrane-bound IL-12 results in T-cell therapy with enhanced potency in preclinical solid tumor models About OBX-115 About Obsidian Therapeutics Obsidian Therapeutics Media Contact:
SOURCE Obsidian Therapeutics |
View original content to download multimedia: